Cargando…

Correlation between pancreatic cancer and metabolic syndrome: A systematic review and meta-analysis

OBJECTIVE: Pancreatic cancer is a globally frequent cause of death, which can be caused by many factors. This meta-analysis was performed to assess the correlation between pancreatic cancer and metabolic syndrome (MetS). METHODS: Publications were identified by searching PubMed, EMBASE, and the Coch...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhong, Lei, Liu, Jifeng, Liu, Shuo, Tan, Guang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10126301/
https://www.ncbi.nlm.nih.gov/pubmed/37113491
http://dx.doi.org/10.3389/fendo.2023.1116582
_version_ 1785030211266412544
author Zhong, Lei
Liu, Jifeng
Liu, Shuo
Tan, Guang
author_facet Zhong, Lei
Liu, Jifeng
Liu, Shuo
Tan, Guang
author_sort Zhong, Lei
collection PubMed
description OBJECTIVE: Pancreatic cancer is a globally frequent cause of death, which can be caused by many factors. This meta-analysis was performed to assess the correlation between pancreatic cancer and metabolic syndrome (MetS). METHODS: Publications were identified by searching PubMed, EMBASE, and the Cochrane Library for studies published until November 2022. Case-control and cohort studies published in English that provided information on the odds ratio (OR), relative risk (RR), or hazard ratio (HR) of metabolic syndrome and pancreatic cancer were included in the meta-analysis. Two researchers separately retrieved the core data from the included Random effects meta-analysis was conducted to summarize the findings. Results were presented as relative risk (RR) and 95% confidence interval (CI). RESULTS: MetS showed a strong association with an increased risk of developing pancreatic cancer (RR1.34, 95% CI1.23–1.46, P<0.001), and gender differences were also observed (men: RR 1.26, 95% CI 1.03–1.54, P=0.022; women: RR 1.64, 95% CI 1.41–1.90, P< 0.001). Moreover, an increased risk of developing pancreatic cancer was strongly linked to hypertension, poor high-density lipoprotein cholesterol, and hyperglycemia (hypertension: RR 1.10 CI 1.01–1.19, P=0.027; low high-density lipoprotein cholesterol: RR 1.24 CI 1.11–1.38, P<0.001; hyperglycemia: RR 1.55, CI 1.42–1.70, P< 0.001). However, pancreatic cancer was independent of obesity and hypertriglyceridemia (obesity: RR 1.13 CI 0.96–1.32, P=0.151, hypertriglyceridemia: RR 0.96, CI 0.87–1.07, P=0.486). CONCLUSIONS: Although further prospective studies are required for confirmation, this meta-analysis indicated a strong relationship between MetS and pancreatic cancer. Regardless of gender, a greater risk of pancreatic cancer existed in people with MetS. Patients with MetS were more likely to develop pancreatic cancer, regardless of gender. Hypertension, hyperglycemia, and low HDL-c levels may largely account for this association. Further, the prevalence of pancreatic cancer was independent of obesity and hypertriglyceridemia. SYSTEMATIC REVIEW REGISTRATION: https://www.crd.york.ac.uk/prospero/, identifier CRD42022368980.
format Online
Article
Text
id pubmed-10126301
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-101263012023-04-26 Correlation between pancreatic cancer and metabolic syndrome: A systematic review and meta-analysis Zhong, Lei Liu, Jifeng Liu, Shuo Tan, Guang Front Endocrinol (Lausanne) Endocrinology OBJECTIVE: Pancreatic cancer is a globally frequent cause of death, which can be caused by many factors. This meta-analysis was performed to assess the correlation between pancreatic cancer and metabolic syndrome (MetS). METHODS: Publications were identified by searching PubMed, EMBASE, and the Cochrane Library for studies published until November 2022. Case-control and cohort studies published in English that provided information on the odds ratio (OR), relative risk (RR), or hazard ratio (HR) of metabolic syndrome and pancreatic cancer were included in the meta-analysis. Two researchers separately retrieved the core data from the included Random effects meta-analysis was conducted to summarize the findings. Results were presented as relative risk (RR) and 95% confidence interval (CI). RESULTS: MetS showed a strong association with an increased risk of developing pancreatic cancer (RR1.34, 95% CI1.23–1.46, P<0.001), and gender differences were also observed (men: RR 1.26, 95% CI 1.03–1.54, P=0.022; women: RR 1.64, 95% CI 1.41–1.90, P< 0.001). Moreover, an increased risk of developing pancreatic cancer was strongly linked to hypertension, poor high-density lipoprotein cholesterol, and hyperglycemia (hypertension: RR 1.10 CI 1.01–1.19, P=0.027; low high-density lipoprotein cholesterol: RR 1.24 CI 1.11–1.38, P<0.001; hyperglycemia: RR 1.55, CI 1.42–1.70, P< 0.001). However, pancreatic cancer was independent of obesity and hypertriglyceridemia (obesity: RR 1.13 CI 0.96–1.32, P=0.151, hypertriglyceridemia: RR 0.96, CI 0.87–1.07, P=0.486). CONCLUSIONS: Although further prospective studies are required for confirmation, this meta-analysis indicated a strong relationship between MetS and pancreatic cancer. Regardless of gender, a greater risk of pancreatic cancer existed in people with MetS. Patients with MetS were more likely to develop pancreatic cancer, regardless of gender. Hypertension, hyperglycemia, and low HDL-c levels may largely account for this association. Further, the prevalence of pancreatic cancer was independent of obesity and hypertriglyceridemia. SYSTEMATIC REVIEW REGISTRATION: https://www.crd.york.ac.uk/prospero/, identifier CRD42022368980. Frontiers Media S.A. 2023-04-11 /pmc/articles/PMC10126301/ /pubmed/37113491 http://dx.doi.org/10.3389/fendo.2023.1116582 Text en Copyright © 2023 Zhong, Liu, Liu and Tan https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Endocrinology
Zhong, Lei
Liu, Jifeng
Liu, Shuo
Tan, Guang
Correlation between pancreatic cancer and metabolic syndrome: A systematic review and meta-analysis
title Correlation between pancreatic cancer and metabolic syndrome: A systematic review and meta-analysis
title_full Correlation between pancreatic cancer and metabolic syndrome: A systematic review and meta-analysis
title_fullStr Correlation between pancreatic cancer and metabolic syndrome: A systematic review and meta-analysis
title_full_unstemmed Correlation between pancreatic cancer and metabolic syndrome: A systematic review and meta-analysis
title_short Correlation between pancreatic cancer and metabolic syndrome: A systematic review and meta-analysis
title_sort correlation between pancreatic cancer and metabolic syndrome: a systematic review and meta-analysis
topic Endocrinology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10126301/
https://www.ncbi.nlm.nih.gov/pubmed/37113491
http://dx.doi.org/10.3389/fendo.2023.1116582
work_keys_str_mv AT zhonglei correlationbetweenpancreaticcancerandmetabolicsyndromeasystematicreviewandmetaanalysis
AT liujifeng correlationbetweenpancreaticcancerandmetabolicsyndromeasystematicreviewandmetaanalysis
AT liushuo correlationbetweenpancreaticcancerandmetabolicsyndromeasystematicreviewandmetaanalysis
AT tanguang correlationbetweenpancreaticcancerandmetabolicsyndromeasystematicreviewandmetaanalysis